Ronapreve 120 mg/ml Injection 2's (2 Vials Combip

Ronapreve 120 mg/ml Injection 2's (2 Vials Combip belongs to the group of monoclonal antibodies used in the post-exposure treatment of mild to moderate respiratory illness caused by COVID-19 in people aged 12 years or older, weighing at least 40kgs. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip is used in non-hospitalised cases of COVID-19 that are at risk of progressing to severe disease. 

Ronapreve 120 mg/ml Injection 2's (2 Vials Combip contains Casirivimab and Imdevimab which work by using proteins (monoclonal antibodies) that mimic the natural immune system of the body and fight off the harmful virus. They block the virus attachment and entry into the human cells, thereby preventing the progression of the illness.

A qualified healthcare professional will administer Ronapreve 120 mg/ml Injection 2's (2 Vials Combip. Do not self-administer. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip may cause certain common side effects such as redness, pain and soreness at the injection site. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if these side effects persist. 

It is advisable to inform the doctor if you are allergic to any of its components. Consult your doctor if you are pregnant, planning to get pregnant or are breastfeeding. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip is not authorized for use in patients who require oxygen therapy or hospitalisation due to COVID-19.

Ronapreve 120 mg/ml Injection 2's (2 Vials Combip contains monoclonal antibodies used in the post-exposure treatment of mild to moderate disease caused by SARS-CoV-2. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip works by using monoclonal proteins to imitate the natural defence mechanism of the body. The COVID virus contains a capsid with spike proteins, through which it penetrates into the body cells to cause infection. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip binds to the spike protein of the virus. Thereby blocking the spike protein of the virus from attaching to the human receptor cell and arresting the progress of the disease. Hence, Ronapreve 120 mg/ml Injection 2's (2 Vials Combip finds use in preventing the progression of mild to moderate covid cases to severe cases requiring hospitalisation. Thus, Ronapreve 120 mg/ml Injection 2's (2 Vials Combip finds use in reducing rates of hospitalisation. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip may also be used as post-exposure prophylaxis of coronavirus disease in people who are not fully vaccinated against COVID-19, people with immunocompromising conditions, and in those who are at high risk of being exposed to someone with COVID-19.

It is advisable to inform the doctor if you are allergic to any of its components. Keep your doctor informed if you suffer from any chronic diseasea such as HIV, asthma, cancer, liver disease, kidney problems, heart disease, neurodevelopmental disorders, sickle cell disease or if you have recently had surgery, gastrostomy, tracheostomy or positive pressure ventilation. Offer a detailed medical and vaccination history. Discuss any recent vaccinations with the doctor. Inform the doctor especially if you are on any radiotherapy, immunosuppressant drugs, blood thinners or any other medicines. Consult your doctor if you are planning to get pregnant or are breastfeeding. Ronapreve 120 mg/ml Injection 2's (2 Vials Combip is not meant for use as vaccination and in severe hospitalised cases.

• In case of a fever or rash following Ronapreve 120 mg/ml Injection 2's (2 Vials Combip, do not use any antipyretic or anti-allergic medicines without consulting the doctor.
• In case of worsening symptoms such as changes in BP, wheezing, hives, shortness of breath, weakness or confusion, call your doctor immediately.